FIELD: medicine.
SUBSTANCE: invention relates to the field of medicine, namely to the field of laboratory diagnostics, cardiology, oncology, therapy, and can be used to evaluate the aggregation activity of platelets. Method includes blood sampling, adding an aggregation inducer to the test sample, followed by determining the amount of aggregation, test is performed with whole blood stabilized using low-frequency piezobloodclotelastography (LFPBCEG), for this, 0.07 ml of platelet aggregation inducer ADP is added to a cuvette with a blood sample in a volume of 0.38 ml, then within 10 minutes the curve of intensity of aggregation of thrombocytes is recorded, and the recording is carried out twice: the initial recording is carried out prior to prescribing the drug, and the control recording is carried out after taking an antiplatelet drug, further determine the area of the sector (S), bounded on one side with the curve, on the other – the axis of the abscissa. When the area (S) exceeds the area of the sector (S1), calculated from the reference values of the control group of conditionally healthy individuals, equal to 200–550 p.u., determine an increase in the aggregation activity of thrombocytes, and when the value of the sector area (S) decreases relative to the sector area (S1) determine a decrease in aggregation activity of platelets.
EFFECT: invention provides a reduction in the preparation time of a blood sample for testing, an increase in the accuracy of the method, the possibility of quantitative evaluation of the aggregation activity of platelets.
1 cl, 5 dwg, 1 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR DETERMINING ASPIRIN RESISTANCE | 2019 |
|
RU2700000C1 |
APPARATUS AND METHOD FOR EXPRESS ESTIMATION OF AGGREGATIVE ACTIVITY OF FORMED ELEMENTS OF BLOOD | 2020 |
|
RU2750839C1 |
METHOD FOR ESTIMATION OF INCREASED RISK OF PHLEBOTHROMBOSES FORMATION IN PATIENTS WITH ISCHEMIC HEART DISEASE | 2016 |
|
RU2624859C1 |
METHOD FOR DETERMINING AN ANTICOAGULANT POTENTIAL OF A VASCULAR WALL | 2018 |
|
RU2690856C1 |
METHOD OF INDIVIDUAL PROGNOSIS OF CLINICAL EFFECTIVENESS OF DUAL ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME | 2016 |
|
RU2639772C1 |
METHOD FOR THROMBOCYTE AGGREGATION ACTIVITY DETERMINATION FOR PATIENTS WITH ACUTE CORONARY SYNDROME | 2016 |
|
RU2619858C1 |
METHOD FOR QUANTITATIVE ASSESSMENT OF THROMBOCYTE AGGREGATION ACTIVITY IN PATIENTS WITH NEW CORONAVIRAL INFECTION | 2021 |
|
RU2760095C1 |
DEVICE AND METHOD FOR EXPRESS ASSESSMENT OF FUNCTIONAL STATE OF HAEMOSTASIS SYSTEM | 2018 |
|
RU2693939C1 |
DICALCIUM SALT OF N-(3-HYDROXYBENZOYL)TAURINE, HAVING ANTIAGGREGANT AND ANTITHROMBOTIC ACTIVITY IN COMBINATION WITH CEREBROPROTECTIVE ACTION | 2019 |
|
RU2730835C1 |
DIPOTASSIUM SALT OF N-(4-HYDROXYBENZOYL) TAURINE, HAVING ANTIAGGREGANT AND ANTITHROMBOTIC ACTIVITY | 2019 |
|
RU2731106C1 |
Authors
Dates
2018-09-13—Published
2016-12-21—Filed